All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
It has proved that a subset of alloreactive interactions that include allo-MHC–restricted TCR/MHC recognition events is very analogous to self-restricted TCR/MHC interactions and involves high specificity for MHC-bound peptide. NB20 bound its alloligand HLA-A2-CLG with a Kd in the range of self-restricted interactions and did not bind irrelevant HLA-A2 peptides or other class I MHC molecules, consistent with the properties of the NB20 T-cell clone and analogous to self-restricted TCRs. Use of CLG variants underlined the importance of multiple peptide residues in NB20 recognition, most of which (L5, L6, and M8) have large exposed side chains prominently positioned in the alloligand structure, indicating direct interaction. In contrast, CLG recognition was unaffected by P1 substitution in the least prominent section of CLG.
There are currently no customer reviews or questions for Human anti-LMP2 T cell receptor ((NB20)-4), pCDTCR1 (TCR-YC0634). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION